A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

NCT05966584 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Limited amount of eligible participants

Conditions

Breast Cancer

Interventions

DRUG: Benralizumab
DRUG: fulvestrant or AIs) and PI3K inhibition (alpelisib)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]